Literature DB >> 4335441

Properties of adenyl cyclase from human jejunal mucosa during naturally acquired cholera and convalescence.

L C Chen, J E Rohde, G W Sharp.   

Abstract

The enterotoxin of Vibrio cholerae causes copious fluid production throughout the lenght of the small intestine. As this is thought to be mediated by stimulation of adenyl cyclase, a study has been made of the activity and properties of this enzyme in jejunal biopsy tissue taken from patients during the diarrheal phase of cholera and after recovery. Adenyl cyclase activity during cholera was increased more than twofold relative to the enzyme in convalescence. Under both conditions stimulation by prostaglandin E(1) (PGE(1)) and by fluoride was observed. The responsiveness to PGE(1) was not altered in cholera; the total activity of the fluoride-stimulated enzyme was similar, a finding that suggests cholera toxin stimulates pre-existing enzyme in the intestinal cell. The enzymes during cholera and convalescence were similar in all other properties examined. Optimal Mg(++) concentration was 10 mM; Mn(++) at 5 mM stimulated the enzyme but could not replace Mg(++) except in the presence of 10 mM fluoride. Calcium was markedly inhibitory at concentrations greater than 10(-4) M. The pH optimum was 7.5 and the Michaelis constant (K(m)) for ATP concentration approximated 10(-4) M. Thus the interaction of cholera toxin with human intestinal adenyl cyclase does not alter the basic properties of the enzyme. When biopsy specimens were maintained intact in oxygenated Ringer's solution at 0 degrees C, no loss of activity was observed at 1(1/2) and 3 hr. In contrast, when the cells were homogenized, rapid loss of activity, with a half-life of 90 min was seen even at 0 degrees C. Consequently for comparative assays of human jejunal adenyl cyclase, strict control of the experimental conditions is required. It was under such conditions that a twofold increase in basal adenyl cyclase activity during cholera was observed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4335441      PMCID: PMC302185          DOI: 10.1172/JCI106867

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  SIMPLE CAPSULE FOR MULTIPLE INTESTINAL BIOPSY SPECIMENS.

Authors:  D C CHOUDHURY; G I NICHOLSON; W T COOKE
Journal:  Lancet       Date:  1964-07-25       Impact factor: 79.321

2.  Foodpoisoning caused by Clostridium welchii in cold chicken.

Authors:  M McNICOL; E J McKILLOP
Journal:  Lancet       Date:  1958-04-12       Impact factor: 79.321

Review 3.  Vibrio cholerae enterotoxin and its mode of action.

Authors:  N F Pierce; W B Greenough; C C Carpenter
Journal:  Bacteriol Rev       Date:  1971-03

4.  Intestinal adenyl-cyclase activity in human cholera.

Authors:  L C Chen; J E Rohde; G W Sharp
Journal:  Lancet       Date:  1971-05-08       Impact factor: 79.321

5.  Prostaglandins in amine-peptide-secreting tumours.

Authors:  M Sandler; S M Karim; E D Williams
Journal:  Lancet       Date:  1968-11-16       Impact factor: 79.321

6.  Effects of prostaglandins, theophylline, and cholera exotoxin upon transmucosal water and electrolyte movement in the canine jejunum.

Authors:  N F Pierce; C C Carpenter; H L Elliott; W B Greenough
Journal:  Gastroenterology       Date:  1971-01       Impact factor: 22.682

7.  The relationship of superior mesenteric artery blood flow to gut electrolyte loss in experimental cholera.

Authors:  C C Carpenter; W B Greenough; R B Sack
Journal:  J Infect Dis       Date:  1969-02       Impact factor: 5.226

8.  Intestinal transmural electric potential and its response to glucose in acute and convalescent cholera.

Authors:  D B Sachar; J O Taylor; J R Saha; R A Phillips
Journal:  Gastroenterology       Date:  1969-03       Impact factor: 22.682

9.  Cholera infection and toxin in the rabbit ileal loop.

Authors:  W Burrows; G M Musteikis
Journal:  J Infect Dis       Date:  1966-04       Impact factor: 5.226

10.  Stimulation of intestinal mucosal adenyl cyclase by cholera enterotoxin and prostaglandins.

Authors:  D V Kimberg; M Field; J Johnson; A Henderson; E Gershon
Journal:  J Clin Invest       Date:  1971-06       Impact factor: 14.808

View more
  14 in total

1.  A case of cholera in Kingston, Ont.

Authors:  R Bourdages; I T Beck
Journal:  Can Med Assoc J       Date:  1976-09-04       Impact factor: 8.262

2.  A study of intercellular spaces in the rabbit jejunum during acute volume expansion and after treatment with cholera toxin.

Authors:  D R DiBona; L C Chen; G W Sharp
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

Review 3.  The pathogenesis of cholera and some wider implications.

Authors:  G E Sladen
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

4.  Sequence of events mediating the effect of cholera toxin on rat thymocytes.

Authors:  J M Boyle; J D Gardner
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

5.  Localization of the action of cholera toxin on adenyl cyclase in mucosal epithelial cells of rabbit intestine.

Authors:  D K Parkinson; H Ebel; D R DiBona; G W Sharp
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

6.  Effect of cholera toxin on insulin release in monolayer cultures of the endocrine pancreas.

Authors:  C B Wollheim; B Blondel; G W Sharp
Journal:  Diabetologia       Date:  1974-12       Impact factor: 10.122

Review 7.  A new look at infectious gastroenteritis.

Authors:  J W St Geme
Journal:  West J Med       Date:  1974-12

8.  Circulating cyclic nucleotides and amines in human cholera.

Authors:  T Morishita; H Asakura; T Hibi; M Tsuchiya; C Uylangco; L Santiago
Journal:  Gastroenterol Jpn       Date:  1981

9.  Stimulation of human colonic adenylate cyclase.

Authors:  B Simon; H Kather
Journal:  Am J Dig Dis       Date:  1978-01

10.  Mechanism of action of Vibrio cholerae enterotoxin. Effects on adenylate cyclase of toad and rat erythrocyte plasma membranes.

Authors:  V Bennett; P Cuatrecasas
Journal:  J Membr Biol       Date:  1975-06-03       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.